To investigate whether our in silico models can generate realistic survival curves as observed in late-stage immunotherapy trials, we fitted the models to three different datasets: (1) the north central cancer treatment group (NCCTG) lung cancer survival dataset34; (2) the CA184-024 trial (ipilimumab+dacarbazine vs. dacarbazine in previously untreated metastatic melanoma35); and (3) the CheckMate 066 trial (nivolumab+placebo vs. dacarbazine + placebo in treatment-naive metastatic melanoma patients without BRAF mutation36). This evidence concerns the gene BRAF and metastatic melanoma.